ISARIC
  • Home
  • About
    • About
    • Hubs
    • Membership
    • People
  • Research
    • Research
    • Acute Respiratory Infection
    • Bubonic plague
    • COVID-19
    • Dengue
    • Ebola and other Filoviruses
    • H5Nx
    • Lassa fever
    • Nipah
    • Mpox
    • Severe Acute Hepatitis
  • Resources
    • Clinical Characterisation Protocol
    • Community Engagement
    • Core Outcome Sets
    • Current Opportunities
    • Data
    • Outputs
    • Resources
    • Stigma
  • Increasing Capacity
    • Increasing Capacity
    • CREDO
    • ISARIC Leadership Programme for Scientists
  • News & Events
    • News
    • Events
Select Page

Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies

by Eamonn | May 3, 2024

Tecovirimat for Monkeypox in Central African Republic under Expanded Access

by Eamonn | May 3, 2024

Final Report – Analysis of a Clinical Trial: Ribavirin and The Treatment Of Lassa Fever

by Wajeeha Malik | Apr 24, 2024

This is a copy of the Report Analysis of a Clinical Trial for Ribavirin and the Treatment of Lassa Fever. The data were collected by the US Centers for Disease Control under their IND 17186.

Addressing stigma in infectious disease outbreaks: a crucial step in pandemic preparedness

by Eamonn | Apr 23, 2024

Characteristics and outcomes of an international cohort of 400,000 hospitalised patients with Covid-19

by Eamonn | Apr 23, 2024

« Older Entries
Next Entries »

Our Mission
Contact us
Opportunities
Funders
News

Follow ISARIC on X

Apply for membership
© ISARIC 2023 | Accessibility | Terms & Conditions | Site by Herd

Cookies Policy

Our Website uses cookies to improve your experience. Please visit our Cookies page for more information about cookies and how we use them.

Close